Heidelberg Pharma AG
XETRA:HPHA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
J
|
Jiangxi Sunshine Dairy Co Ltd
SZSE:001318
|
CN |
|
Nanjing Hicin Pharmaceutical Co Ltd
SZSE:300584
|
CN |
Heidelberg Pharma AG
Total Receivables
Heidelberg Pharma AG
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Heidelberg Pharma AG
XETRA:HPHA
|
Total Receivables
€2.3m
|
CAGR 3-Years
17%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Total Receivables
€984.9m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
|
CureVac NV
NASDAQ:CVAC
|
Total Receivables
€22.6m
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Total Receivables
€6.9m
|
CAGR 3-Years
49%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Total Receivables
€196.9m
|
CAGR 3-Years
18%
|
CAGR 5-Years
7%
|
CAGR 10-Years
0%
|
|
|
Formycon AG
XETRA:FYB
|
Total Receivables
€30.8m
|
CAGR 3-Years
37%
|
CAGR 5-Years
44%
|
CAGR 10-Years
25%
|
|
Heidelberg Pharma AG
Glance View
Heidelberg Pharma AG is a biopharmaceutical company, which engages in the research and development of drugs for cancer patients. The company is headquartered in Ladenburg, Baden-Wuerttemberg and currently employs 89 full-time employees. The company went IPO on 2006-11-13. The firm focuses on the research and development of therapy treatments for oncology area. The company aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Company’s pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. The company also offers preclinical contract research services.
See Also
What is Heidelberg Pharma AG's Total Receivables?
Total Receivables
2.3m
EUR
Based on the financial report for Nov 30, 2025, Heidelberg Pharma AG's Total Receivables amounts to 2.3m EUR.
What is Heidelberg Pharma AG's Total Receivables growth rate?
Total Receivables CAGR 5Y
9%
Over the last year, the Total Receivables growth was -61%. The average annual Total Receivables growth rates for Heidelberg Pharma AG have been 17% over the past three years , 9% over the past five years .
